

Meningitis Research Foundation Conference 2025

Provisional Programme

Stay tuned as additional presentations and panel details are confirmed. Please note that all event content is subject to change without prior notice.

Day 1 – Tuesday 18 November

8.15-9.00 Registration, Coffee, Exhibitions and Posters

9.00-9.15 Welcome, Vinny Smith, **Chief Executive Meningitis Research Foundation and Confederation of Meningitis Organisations**

9.15-10.45 Session 1 (A): The lifetime impact of meningitis – Personal testimony & Meningitis Belt

Chair: Professor Nora Groce, University College London

This first session of Day 1 will explore the lifetime impact of meningitis through a combination of lived experiences and data-driven country evidence. The session will begin with personal testimonies by those affected by meningitis, followed by presentations examining the evidence for meningitis sequelae, with a focus on regions within the meningitis belt. During this session, delegate feedback will be collected at the beginning and end of this session through polls.

- Low income setting personal testimony, **Tendai David Muranganwa, Confederation of Meningitis Organisations**
- High income setting personal testimony, **Isabelle Weall, United Kingdom**
- Evidence from Burkina Faso, **Dr Robert Zoma, Davycas International**
- Evidence from Niger, **Dr Matthew Coldiron, Médecins Sans Frontières**
- Evidence from Nigeria, **Dr Fatima Bukar, Nigeria Centre for Disease Control and Prevention**

10.45-11.05 Coffee, Exhibitions and Posters

11.05-12.30 Session 1 (B): The lifetime impact of meningitis – Middle & High Income Settings, Panel Discussion

This session will build upon Session 1 (A) with further presentations focusing on the evidence for meningitis sequelae in more resource-rich settings. During this session, delegates will be asked to take part in an interactive poll to identify the most important challenges and research priorities. This session will conclude with a panel discussion on challenges to better understanding the lifetime impact of meningitis.

- The development of new immunotherapies for bacterial meningitis starts from understanding brain immunity, **Dr Federico Iovino, Karolinska Institutet**
- Evidence from Brazil, **Dr Paula Reges, Oswaldo Cruz Foundation**
- Evidence from India, **Dr Nethravathi, National Institute of Mental Health and Neurosciences**

Confirmation of additional panel members:

- **Professor Nora Groce, University College London**
- **Professor Anne Von Gottberg, National Institute for Communicable Diseases**

13.30-15.00 Session 2 (A): Meningitis: insights into an evolving picture

Chair: Professor Dominique Caugant, Norwegian Institute of Public Health

*This session will delve into emerging patterns in meningitis etiology and epidemiology, including rising pathogens such as *Klebsiella pneumoniae* in neonatal infections, the role of mass gatherings in disease transmission, antimicrobial resistance concerns, and the influence of environmental risk factors on outbreaks.*

- *Klebsiella pneumoniae*: a leading cause of neonatal and childhood meningitis, **Professor Kat Holt, London School of Hygiene and Tropical Medicine**
- Update on Umrah- and Middle Eastern/Asian travel-related meningococcal serogroup W invasive disease, **Dr Stephen Clark, UK-HSA**
- Associations between environmental risk factors and epidemics, **Molly Cliff, University of Cambridge**

15.30-16.55 Session 2 (B): Meningitis: insights into an evolving picture, Panel Discussion

Chair: Professor Dominique Caugant, Norwegian Institute of Public Health

As the final session of Day 1, this session complements Session 2 (A) by sharing recent data from the United Kingdom, highlighting the latest national picture. It will also present research on meningococcal bacteria carriage among teenagers and young adults, concluding with a discussion on defining research priorities for understanding carriage according to different age groups.

- Meningitis in the UK: now and the future, **Dr Shamez Ladhani, UK-HSA**
- Evaluating the Effect of Immunisation with Group B Meningococcal Vaccines on Meningococcal Carriage in Adolescents: The Be on the Team Study, **Professor Caroline Trotter, University of Cambridge**
- Meningococcal carriage in freshers following arrival at the University of Nottingham, **Dr Neil Oldfield, University of Nottingham**
- Research priorities for meningitis in older age groups, **Professor Muhamed Kheir Taha, Institut Pasteur Paris**

Confirmation of additional panel members:

- **Professor Ener Cagri-Dinleyici, Eskisehir Osmangazi University**

16.55-17.00 Day 1 Close, Vinny Smith, Chief Executive Meningitis Research Foundation and Confederation of Meningitis Organisations

Day 2 – Wednesday 19 November

9.00-9.05 Welcome to Day 2, Vinny Smith, Chief Executive Meningitis Research Foundation and Confederation of Meningitis Organisations

9.05-10.30 Session 3: Advances in meningitis diagnosis and clinical management

Chair: Dr Matthew Coldiron, Médecins Sans Frontières (MSF)

First session of Day 2 will highlight recent progress in clinical approaches to meningitis, with presentations covering advances in diagnostic techniques and updated treatment strategies. This session will explore the introduction of new guidelines on managing serious bacterial infections in infants, followed by a panel discussion.

- Brain Infections Global – a sustainable program to improve the management of brain infections in Africa, Asia and Latin America, **Professor Tom Solomon, CBE, Liverpool School of Tropical Medicine**
- Latest developments in clinical management of Tuberculous meningitis, **Dr Fiona Cresswell, London School of Hygiene and Tropical Medicine**
- Latest developments in clinical management of Cryptococcal meningitis, **Professor Joe Jarvis, London School of Hygiene and Tropical Medicine**

10.30-10.45 Coffee, Exhibitions & Posters

10.45-12.30 Session 4: Mid-point progress of the WHO Defeating Meningitis by 2030 Global Road Map

Chair: Dr Marie-Pierre Preziosi, World Health Organization

This session will provide a comprehensive update on the WHO Global Roadmap to Defeat Meningitis by 2030, presented by the WHO. During this session, delegate feedback will be collected at the beginning and end of this session through polls, capturing views on progress and research priorities at this important midpoint in the Road Map.

- Global epidemiology overview, **Professor Caroline Trotter, University of Cambridge**
- WHO Road Map mid-point progress review, **Dr Virginia Benassi, World Health Organization**
- AFRO Perspective of progress and research priorities, **Dr Andre Bita, WHO AFRO**
- PAHO Perspective of progress and research priorities, **Dr Nathalie El Omeiri, WHO PAHO**
- EMRO Perspective of progress and research priorities, **Dr Messeret Eshtu Shibeshi, WHO EMRO**

12.30-13.30 Lunch, Exhibitions & Posters

13.30-15.00 Session 5: Strategies for prevention and epidemic control: optimising use of vaccines and developing next-generation solutions

Chair: Dr Brenda Kwambana-Adams, Malawi Liverpool Wellcome Trust

This session will examine the latest progress and lessons learnt from the roll out of meningitis vaccines and the novel use of DHIS2, drawing on real-world experiences from low-income settings. It will also address results from the Lion MenB trial, explore the implications of Gavi replenishment for meningitis control and examine broader challenges related to vaccine access and equity. This session will conclude with a to be confirmed panel discussion.

- Looking ahead: meningitis vaccination in Gavi 6.0, **Beth Evans, Gavi Vaccine Alliance**
- Latest progress on pneumococcal vaccine usage in children after March SAGE meeting, **Professor Anthony Scott, London School of Hygiene and Tropical Medicine**
- Scheduling infant vaccines for maximum protection: results from the Lion MenB trial, **Dr Natasha Thorn, City St George's, University of London**
- Update on GBS vaccine development and serocorrelates, **Dr Konstantinos Karampatsas, City St George's, University of London**
- How equitable is meningitis vaccine access today? **Professor Nicole Basta, McGill University**

15.00-15.20 Coffee, Exhibitions & Posters

15.20-15.50 Session 6: Poster Presentations and Award

Chair: Dr Kanny Diallo, Centre Suisse de Recherches Scientifiques (CSRS)

This short session will feature oral presentations from the authors of the top five posters selected through the conference abstract call, giving them an opportunity to showcase their research. This session will conclude with the announcement of the best poster award, as chosen by the steering committee.

15.50-16.55 Session 7 Enhancing global meningitis surveillance: current efforts and future directions

Chair: Professor Rob Heyderman, University College London

This final session will showcase the new Meningitis Progress Tracker as a lead-in to ongoing efforts to enhance global meningitis surveillance, featuring talks on the Meningitis Pathogen Genome Value Chain analysis in Nigeria and Chad, the development of new metadata frameworks, and developments in the use of DHIS2. During this session, delegate feedback will be collected at the beginning and end of this session through polls.

- Meningitis Pathogen Genome Value Chain analysis in Nigeria and Chad, **Dr Kanny Diallo, Centre Suisse de Recherches Scientifiques (CSRS)**
- Establishing Global Standards for Meningitis Metadata to support Genome-Based Surveillance, **Dr Samy Taha, Institut Pasteur Paris**
- Leveraging DHIS2 Innovations to Strengthen Meningitis Surveillance and Sequelae Monitoring in Africa **Dr Clement Lingani, World Health Organization**
- Meningitis Progress Tracker, **Brian Davies, Meningitis Research Foundation**

16.55-17.00 Closing remarks, Vinny Smith, **Chief Executive Meningitis Research Foundation and Confederation of Meningitis Organisations**

We will share more information as the programme develops.

For any questions on the programme please contact Mariusz Kosek, Senior Research and Events Officer, at mariuszk@meningitis.org

Stay up to date by signing up to our mailing list:

<https://www.meningitis.org/healthcare-professionals/stay-up-to-date>



Meningitis Research Foundation Conference 2025 has been made possible thanks to funding from Wellcome (Grant ref. 228143/Z/23/Z) and sponsorship by Pfizer Limited. This conference is operated independently, with Wellcome and Pfizer Ltd having no editorial control over its content.